Regeneron (REGN Quick QuoteREGN - Free Report) reported $3.55 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 12.3%. EPS of $11.56 for the same period compares to $10.24 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $3.38 billion, representing a surprise of +4.84%. The company delivered an EPS surprise of +9.37%, with the consensus EPS estimate being $10.57.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Regeneron performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Eylea (Aflibercept)- US

  : $1.53 billion compared to the $1.52 billion average estimate based on five analysts. The reported number represents a change of +2.3% year over year.

• Revenues- Praluent (alirocumab)- US

  : $56.10 million versus $40.27 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +38.5% change.

• Revenues- Evkeeza- US

  : $31 million versus $24.20 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +63.2% change.

• Revenues- Libtayo- ROW

  : $115 million versus $109.95 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +44.1% change.

• Revenues- Net product sales

  : $1.92 billion compared to the $1.85 billion average estimate based on eight analysts. The reported number represents a change of +8.3% year over year.

• Revenues- Other Revenue

  : $104.50 million versus the eight-analyst average estimate of $110.39 million. The reported number represents a year-over-year change of +50.8%.

• Revenues- Collaboration

  : $1.52 billion versus $1.44 billion estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +15.7% change.

• Total Sanofi collaboration revenue

  : $1.15 billion versus $1.05 billion estimated by six analysts on average.

• Total Bayer collaboration revenue

  : $375.10 million versus $375.33 million estimated by six analysts on average.

• Revenues- Libtayo- Total

  : $297.40 million versus the four-analyst average estimate of $284.84 million. The reported number represents a year-over-year change of +41.6%.

• Revenues- Dupixent (dupilumab)- Total

  : $3.56 billion versus $3.44 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +27.5% change.

• Revenues- Praluent (alirocumab)- Total

  : $191.90 million versus the three-analyst average estimate of $156.79 million. The reported number represents a year-over-year change of +36.8%.

View all Key Company Metrics for Regeneron here>>>

Shares of Regeneron have returned +5.4% over the past month versus the Zacks S&P 500 composite's +1.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.